POLITICO's Morning Health Care newsletter highlighted PAREA's work on the EU Biotech Act on August 26, in a piece titled "Spotlighting mental health innovation in the Biotech Act." The newsletter's "Driving the Day" section covered our central message to EU lawmakers: mental health innovation needs to be an explicit focus of the Biotech Act.

In May, PAREA convened leaders from 25 countries in Brussels, representing some 30 national psychedelic organisations. The preceding day, we had participated in a meeting at the European Parliament to discuss access to psychedelics in Ukraine.

PAREA is pleased to officially welcome three new organizations as our newest Community Supporters: Rights Reporter Foundation, ACER Integration, and International Jungian Psychedelic Association (IJPA).

On July 16, news broke that Eli Lilly, the world's largest pharma company, acquired the psychedelic biotech AtaiBeckley in a multi-billion transaction. AtaiBeckley is developing an intranasal 5-MeO-DMT for treatment-resistant depression, which is just entering its Phase 3 trial.

A series of federal announcements in the United States yesterday illustrates the rapid pace of change in public policy surrounding psychedelic therapies and mental health innovation. In a single wave of announcements, several US federal agencies have publicly expressed support for psychedelics-related research, regulatory preparation, and healthcare system readiness.

We are delighted to have been invited to the 12th European Academy of Neurology (EAN) Congress, currently taking place in Geneva, Switzerland. PAREA's Founder, Tadeusz, and Project Officer, Francisca, are representing PAREA with a booth in the Neurohood exhibition area. This marks our second time exhibiting at the EAN Congress, following last year's successful participation in Helsinki. 

The Psychedelic Lived Experiences Initiative is dedicated to elevating patient and participant voices in psychedelic care, grounded in the conviction that lived experience constitutes genuine expertise. Its work spans advocacy, community building, and education.

PAREA has submitted its contribution to the European Commission’s consultation on the EU4Health 2027 Work Programme. Established in the aftermath of the COVID-19 pandemic, EU4Health is the EU’s flagship health funding programme, designed to strengthen the European Health Union, improve health system resilience, and support common health priorities across Member States.

PAREA has submitted formal recommendations to the European Commission’s public consultation on the upcoming European Biotech Act, urging policymakers to ensure that mental health innovation is explicitly reflected in one of the EU’s most important emerging health and industrial policy initiatives.

PAREA's annual Impact Report, compiling all our activities, contributions and achievements for the year of 2025, is now available! 2025 was a year of clear acceleration for psychedelic therapies and mental health innovation across Europe, and PAREA played a central role in shaping the policy landscape.

On 7 May 2026, PAREA convened the first European Forum of National Psychedelic Societies in Brussels, bringing together representatives of organisations from 25 countries working on psychedelic research, policy, and access across Europe.

On 6 May 2026, policymakers, clinicians, researchers, veterans, and civil society representatives gathered at the European Parliament in Brussels for a timely discussion on mental health care in Ukraine and the role that evidence-based psychedelic therapies may play in addressing war-related trauma.

The French National Agency for the Safety of Medicines and Health Products (ANSM) announced its decision to establish compassionate access to generic ketamine for patients in suicidal crisis.

These past days, we’ve been at the 34th European Psychiatric Association Congress in Prague, themed “Mental Health: Improving Care and Expanding Horizons”. At our dedicated PAREA stand, we engaged with clinicians and professionals interested in exploring the role of psychedelic therapies in mental health care.

A psychedelic compound, bretisilocin, has entered the European Medicines Agency’s PRIME (Priority Medicines) scheme for the treatment of major depressive disorder. This marks a notable development for psychedelic research and regulatory engagement in Europe.

The 69th session of the UN Commission on Narcotic Drugs took place at the Vienna International Centre in Austria from 9 to 13 March, bringing together governments, international organisations, researchers, and civil society to discuss global drug policy.

Founded in 2022 by Dr Grace Blest Hopley, Hystelica is a nonprofit organization dedicated to advancing psychedelic science for women. Its work focuses on research, advocacy, and education to ensure that women’s health and female biology are meaningfully considered in the development of psychedelic medicine.

On February 17, Compass Pathways released topline data from its second Phase 3 trial, COMP006. The trial enrolled 581 participants and administered two doses of COMP360 25 mg, 10mg or 1 mg, administered three weeks apart.

On February 13, 2026, Spain’s Congress of Deputies hosted its first parliamentary conference dedicated to psychedelic-assisted psychotherapies. Held in the Ernest Lluch Chamber, the four hour event marked a shift from peripheral debate to institutional engagement.

Please save the date for an upcoming public webinar on addressing psychological distress in palliative care, centred on the EU-funded PsyPal project (Psilocybin Therapy for Psychological Distress in Palliative Care Patients).